An NCCN survey taken during the period of congressional debate over new federal healthcare legislation, reports how oncology professionals feel about the possible repeal and replacement of the ACA.
Induction Chemotherapy Combination Boosts PFS/OS in Cervical Cancer
Data from the INTERLACE trial shows induction chemotherapy followed by chemoradiotherapy prolongs overall survival in locally advanced cervical cancer.
Empowering Awareness to Address Rising Gynecological Cancer Incidence
Ginger J. Gardner, MD, FACOG, highlights disease prevention innovations and other ongoing efforts to empower education in the gynecologic cancer field.
Inavolisib-Based Therapy Boosts Progression-Free Survival in Breast Cancer
Inavolisib-based therapy reaches the primary end point of the phase 3 INAVO120 study among patients with PIK3CA-mutated breast cancer.
Leveraging Ex Vivo Gene Therapy Advancements in Hemoglobinopathies and Metabolic Diseases
A panel of expert pharmacists provides their perspectives on gene therapy agents such as exagamglogene autotemcel in the management of sickle cell disease.
Atezolizumab/Matched-Targeted Therapy Improves OS in Anaplastic Thyroid Cancer
Patients with anaplastic thyroid cancer had a significant boost to overall survival with atezolizumab and targeted therapy.
Study Shows Post-Mastectomy Disparities in Breast Cancer Minority Groups
Findings speak to the need of cultural, racial, and ethnic inclusion when designing breast cancer trials and developing patient-reported outcome measures.